Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyu-Pyo Kim

Showing results (181-190 of 217) with videos related to

Pageof 22
Sort By:
The Oncologist|March 20, 2023
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study PlatformAndrew H Ko, Kyu-Pyo Kim, Jens T Siveke, et al.
Cancer Research and Treatment|September 4, 2020
Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3- CD4+ T Cells in Biliary Tract CancerHyung-Don Kim, Jwa Hoon Kim, Yeon-Mi Ryu, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|February 23, 2024
Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinomaHyunseok Yoon, Yeokyeong Shin, Baek-Yeol Ryoo, et al.
Cancer Research and Treatment|November 10, 2020
Adjuvant Chemotherapy for Resected Ampulla of Vater Carcinoma: Retrospective Analysis of 646 PatientsJwa Hoon Kim, Jae Ho Jeong, Baek-Yeol Ryoo, et al.
Apoptosis : an International Journal on Programmed Cell Death|March 22, 2014
NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotypeSeung-Woo Hong, Jae-Sik Shin, Jai-Hee Moon, et al.
The Lancet. Oncology|October 16, 2012
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trialYong Sang Hong, Young Suk Park, Ho Yeong Lim, et al.
Cancers|March 10, 2022
Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Propensity Score-Matched AnalysisYoung Seob Shin, Hee Hyun Park, Jin-Hong Park, et al.
Cancers|March 1, 2019
Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective AnalysisChanghoon Yoo, Sang Hyun Shin, Kyu-Pyo Kim, et al.
Anticancer Research|February 10, 2017
Postoperative Radiotherapy for Pancreatic Cancer with Microscopically-positive Resection MarginSunmin Park, Song Cheol Kim, Seung-Mo Hong, et al.
Free Radical Biology & Medicine|March 26, 2016
L-Ascorbic acid can abrogate SVCT-2-dependent cetuximab resistance mediated by mutant KRAS in human colon cancer cellsSoo-A Jung, Dae-Hee Lee, Jai-Hee Moon, et al.
Pageof 22

Showing results (181-190 of 217) with videos related to

Sort By:
Pageof 22
The Oncologist|March 20, 2023
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study PlatformAndrew H Ko, Kyu-Pyo Kim, Jens T Siveke, et al.
Cancer Research and Treatment|September 4, 2020
Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3- CD4+ T Cells in Biliary Tract CancerHyung-Don Kim, Jwa Hoon Kim, Yeon-Mi Ryu, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|February 23, 2024
Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinomaHyunseok Yoon, Yeokyeong Shin, Baek-Yeol Ryoo, et al.
Cancer Research and Treatment|November 10, 2020
Adjuvant Chemotherapy for Resected Ampulla of Vater Carcinoma: Retrospective Analysis of 646 PatientsJwa Hoon Kim, Jae Ho Jeong, Baek-Yeol Ryoo, et al.
Apoptosis : an International Journal on Programmed Cell Death|March 22, 2014
NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotypeSeung-Woo Hong, Jae-Sik Shin, Jai-Hee Moon, et al.
The Lancet. Oncology|October 16, 2012
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trialYong Sang Hong, Young Suk Park, Ho Yeong Lim, et al.
Cancers|March 10, 2022
Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Propensity Score-Matched AnalysisYoung Seob Shin, Hee Hyun Park, Jin-Hong Park, et al.
Cancers|March 1, 2019
Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective AnalysisChanghoon Yoo, Sang Hyun Shin, Kyu-Pyo Kim, et al.
Anticancer Research|February 10, 2017
Postoperative Radiotherapy for Pancreatic Cancer with Microscopically-positive Resection MarginSunmin Park, Song Cheol Kim, Seung-Mo Hong, et al.
Free Radical Biology & Medicine|March 26, 2016
L-Ascorbic acid can abrogate SVCT-2-dependent cetuximab resistance mediated by mutant KRAS in human colon cancer cellsSoo-A Jung, Dae-Hee Lee, Jai-Hee Moon, et al.
Pageof 22